Briefing
Atezolizumab plus sacituzumab govitecan to prevent recurrence in TNBC (ASPRIA)
Phase 2 trial of atezolizumab plus sacituzumab govitecan for six cycles in triple-negative breast cancer. The registry primary outcome is the rate of undetectable circulating tumor cell-free DNA. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting